Table 1.
Patient characteristics.
Fig 1.
Distribution of individual comorbidities.
Individual comorbidities among 194 AML patients as assessed by the three indices, respectively. Hepatic diseases are not assessed by the ACE-27 score, and infections are only assessed by the HCT-CI.
Table 2.
Distribution of comorbidities.
Fig 2.
Survival curves according to the 3 comorbidity indices HCT-CI, ACE-27 and CIRS-G.
Risk groups based on comorbidity were stratified by HCT-CI, ACE-27 score and CIRS-G in all 194 patients and differences in survival between groups were tested using the long-rank test.
Table 3.
Cox proportional hazard regression model with factors predicting overall survival for the entire cohort.
Fig 3.
Overall survival for the entire patient cohort and for different treatment strategies.
Kaplan-Meier analysis was performed and the effect of treatment on OS was tested using the long-rank test. (A) OS in the entire patient cohort. The median OS was 17 months. (B) OS in the patient groups according to treatment strategy. The median OS of the 173 patients treated intensively was 18 months (blue line) while the 21 patients who received palliative treatment, had a median OS of one month (green line).
Table 4.
Factors associated with early death (ED) and overall survival (OS) in patients with intensive induction chemotherapy.
Fig 4.
Distribution of ACE-27 categories in different age groups.
Distribution of ACE-27 score of none, mild, moderate and severe comorbidities among four age groups in all 194 AML patients. 22 patients were younger than 41 years, 53 patients were between 41 and 59 years old, 119 patients were more than 60 and 58 patients more than 70 years old. Increasing age was significantly associated with higher ACE-27 score as analyzed by x2 test (p < .000).